Plus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at
Dose escalation trial demonstrates preliminary safety and efficacy results including median overall survival of 10 months for patients with leptomeningeal...
Source: globenewswire.com
Page 3 - March Hedrick News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from March Hedrick. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In March Hedrick Today - Breaking & Trending Today
Positive Results Unveiled for Targeted CNS Cancer Treatment in Recent Study by Plus Therapeutics
Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company, presented promising outcomes from the ReSPECT-LM clinical study at the SNO/ASCO CNS Cancer Conference. The study assesses rhenium (186Re) obisbemeda’s effectiveness in treating leptomeningeal metastases (LM), it said. Rhenium (186Re) obisbemeda showed effective circulation in cerebrospinal fluid for a week and had minimal severe side […]
Source: yahoo.com
Plus Therapeutics Announces Key Opinion Leader Roundtable on New Clinical Trial Data Being Presented at the 2023 SNO/ASCO CNS Cancer Conference
Trial investigators and company management to discuss latest data from the ReSPECT-LM leptomeningeal metastases clinical trial Webinar scheduled for Friday, August 11, 2023 at 8:00 a.m. ET AUSTIN,...
Source: marketscreener.com
Plus Therapeutics Announces Key Opinion Leader Roundtable
Trial investigators and company management to discuss latest data from the ReSPECT-LM leptomeningeal metastases clinical trial Webinar scheduled for...
Source: globenewswire.com
Plus Therapeutics Announces FDA Meeting Summary for Lead Drug Candidate
06.09.2022 - NIH-funded ReSPECT-GBM Phase 2 trial to start in 2022 ReSPECT-GBM Phase 2 to focus on 186RNL dose expansion, safety and efficacy data to support future registrational trial AUSTIN, Texas, Sept. 06, 2022 (GLOBE NEWSWIRE) - Plus Therapeutics, ... Seite 1
Source: wallstreet-online.de